Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. (Q46954898)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Tatjana Traub-Weidinger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Margarida Rodrigues

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Shuren Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bettina Ibi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Irene Virgolini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

21 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

532-540

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-005-0020-3

17 January 2020

exact match

0 references

cites work

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

12 December 2020

Peptide receptor imaging and therapy

1 reference

12 December 2020

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy

1 reference

12 December 2020

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

12 December 2020

Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC)

1 reference

12 December 2020

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

1 reference

12 December 2020

Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors

1 reference

12 December 2020

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours

1 reference

12 December 2020

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

1 reference

12 December 2020

Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

1 reference

12 December 2020

Advances in chemotherapy and biotherapy of endocrine tumors.

1 reference

12 December 2020

Clinical aspects of glucagon-producing islet cell tumors

1 reference

12 December 2020

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

1 reference

12 December 2020

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

12 December 2020

Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma

1 reference

12 December 2020

The glucagonoma syndrome: Surgically curable diabetes

1 reference

12 December 2020

Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy

1 reference

12 December 2020

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history

1 reference

12 December 2020

Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies

1 reference

12 December 2020

In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT

1 reference

12 December 2020

Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

1 reference

12 December 2020

Low-energy electron emitters for targeted radiotherapy of small tumours.

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

From the magic bullet to an effective therapy: the peptide experience

1 reference

12 December 2020

Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors

1 reference

12 December 2020

In vivo somatostatin receptor imaging in medullary thyroid carcinoma

1 reference

12 December 2020

Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung

1 reference

12 December 2020

The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma.

1 reference

12 December 2020

10.1007/S00259-005-0020-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16491425%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference